| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.28.5.614 |
| P698 | PubMed publication ID | 18447660 |
| P50 | author | Luis L Ostrosky-Zeichner | Q95627987 |
| Melissa D. Johnson | Q50728607 | ||
| P2093 | author name string | John Mohr | |
| James S Lewis | |||
| Travis Cooper | |||
| P2860 | cites work | Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality | Q24530412 |
| Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia | Q24563657 | ||
| A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma | Q24803510 | ||
| The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase | Q27932751 | ||
| A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 | ||
| NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 | ||
| Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations | Q42645346 | ||
| The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers | Q42678650 | ||
| Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. | Q42686004 | ||
| Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers | Q43094166 | ||
| In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis | Q43423744 | ||
| Aspergillus infection complicating cardiac transplantation. Report of five cases | Q43472645 | ||
| Risk factors for amphotericin B-induced nephrotoxicity | Q43544333 | ||
| A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group | Q43574526 | ||
| A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation | Q43619964 | ||
| Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia | Q43628333 | ||
| Congestive heart failure associated with itraconazole | Q43638251 | ||
| Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia | Q43653695 | ||
| Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies | Q43655282 | ||
| Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. | Q43732838 | ||
| Transient hypoparathyroidism due to amphotericin B-induced hypomagnesemia in a patient with beta-thalassemia | Q43748477 | ||
| A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis | Q43757967 | ||
| The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy | Q43797281 | ||
| Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial | Q43801360 | ||
| Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. | Q43823539 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease | Q43945240 | ||
| Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. | Q44064682 | ||
| Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study | Q44074398 | ||
| Lipid formulations of amphotericins: are you a lumper or a splitter? | Q44135232 | ||
| A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis | Q44166464 | ||
| Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study | Q44236247 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Novel antifungal beta-amino acids: synthesis and activity against Candida albicans | Q44301646 | ||
| Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 | ||
| Echinocandins: a new class of antifungal | Q28201851 | ||
| Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 | ||
| Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 | ||
| Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 | ||
| Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 | ||
| Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 | ||
| Risk factors of ventricular fibrillation during rapid amphotericin B infusion | Q28362565 | ||
| Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients | Q28362691 | ||
| Long QT syndrome and torsade de pointes in a patient receiving fluconazole | Q28377092 | ||
| Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis | Q28377349 | ||
| Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review | Q28377356 | ||
| Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions | Q29399166 | ||
| Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 | ||
| Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. | Q30453032 | ||
| Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial | Q30596268 | ||
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus spp. | Q33679625 | ||
| Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits | Q33770019 | ||
| Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 | ||
| Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America | Q33894472 | ||
| Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America | Q33898624 | ||
| A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan | Q33980368 | ||
| Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study | Q33983629 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Antifungal pharmacodynamics: review of the literature and clinical applications | Q34083129 | ||
| Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases | Q34105475 | ||
| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer | Q34114674 | ||
| Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study | Q34123634 | ||
| Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study | Q34196792 | ||
| Glucan synthase inhibitors as antifungal agents | Q34236665 | ||
| Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats | Q34265019 | ||
| Pharmacology of Systemic Antifungal Agents | Q57533011 | ||
| A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis | Q58404248 | ||
| An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy | Q58840045 | ||
| Seroincidence of Coccidioidomycosis during military desert training exercises | Q37576864 | ||
| Effect of salt supplementation on amphotericin B nephrotoxicity | Q39185944 | ||
| Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation | Q39540249 | ||
| Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations | Q39954432 | ||
| Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers | Q40284175 | ||
| Effect of infusion rates on toxicity of amphotericin B. | Q40284666 | ||
| Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis | Q40390928 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial | Q40536892 | ||
| A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients | Q40577742 | ||
| Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle | Q40596481 | ||
| A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group | Q40612309 | ||
| Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution | Q40664606 | ||
| In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. | Q40668115 | ||
| Pretreatment regimens for adverse events related to infusion of amphotericin B. | Q40686510 | ||
| Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia | Q40847963 | ||
| Meperidine for the treatment of shaking chills and fever | Q40862172 | ||
| Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature | Q41218000 | ||
| A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 | ||
| Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. | Q41736571 | ||
| Sodium protects against nephrotoxicity in patients receiving amphotericin B. | Q42196559 | ||
| Risk factors for Amphotericin B-associated nephrotoxicity | Q42199876 | ||
| Must we really fear toxicity of conventional amphotericin B in oncological patients? | Q42536416 | ||
| Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant | Q42556554 | ||
| Intravenous itraconazole | Q34284268 | ||
| Posaconazole as salvage therapy for zygomycosis | Q34301611 | ||
| Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection | Q34352014 | ||
| Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis | Q34352109 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Correlates of acute renal failure in patients receiving parenteral amphotericin B. | Q34384041 | ||
| Epidemiology and outcome of zygomycosis: a review of 929 reported cases | Q34440240 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Intrathecal amphotericin in the management of coccidioidal meningitis | Q34461613 | ||
| Infection in organ-transplant recipients | Q34471508 | ||
| Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? | Q34490092 | ||
| Disseminated phaeohyphomycosis: review of an emerging mycosis | Q34498615 | ||
| Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases | Q34498982 | ||
| Long QTc interval and torsade de pointes caused by fluconazole | Q34569221 | ||
| Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease | Q34574325 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| State-of-the-art review of pulmonary fungal infections | Q34692250 | ||
| Histoplasmosis and blastomycosis | Q34734019 | ||
| Safety and tolerability of caspofungin acetate in the treatment of fungal infections | Q34746958 | ||
| Voriconazole: a new triazole antifungal agent | Q35069136 | ||
| Caspofungin: the first in a new class of antifungal agents | Q35214623 | ||
| Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations | Q35565314 | ||
| New approaches to the risk of Candida in the intensive care unit | Q35587111 | ||
| QT prolongation with antimicrobial agents: understanding the significance | Q35771493 | ||
| Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B | Q35843584 | ||
| Prophylaxis and treatment of invasive candidiasis in the intensive care setting | Q35889819 | ||
| Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. | Q35966128 | ||
| Invasive candidiasis in the intensive care unit | Q36408361 | ||
| Zygomycosis: the re-emerging fungal infection | Q36433729 | ||
| Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies | Q36506378 | ||
| Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases | Q36516342 | ||
| Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality | Q36715387 | ||
| Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats | Q36757423 | ||
| Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics | Q44440957 | ||
| A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. | Q44440960 | ||
| Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group | Q44474075 | ||
| Amphotericin B: time for a new "gold standard". | Q44527998 | ||
| Effects of amphotericin B and caspofungin on histamine expression | Q44551295 | ||
| The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? | Q44573526 | ||
| Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 | ||
| Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients | Q44691631 | ||
| Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients | Q44733428 | ||
| Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial | Q44753214 | ||
| Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis | Q44800864 | ||
| Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. | Q44952024 | ||
| Prophylaxis for invasive candidiasis in the intensive care unit: is it time? | Q44970985 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis | Q45096984 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients | Q45097002 | ||
| Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study | Q45141879 | ||
| Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections | Q45186788 | ||
| Treatment of Chronic Pulmonary Histoplasmosis | Q45216504 | ||
| Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group | Q45769494 | ||
| Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies | Q46366403 | ||
| A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. | Q46414215 | ||
| Treatment of Candida infections with amphotericin B lipid complex | Q46421806 | ||
| Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients | Q46421810 | ||
| Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex | Q46421814 | ||
| Study of renal safety in amphotericin B lipid complex-treated patients | Q46421821 | ||
| Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection | Q46486677 | ||
| Refractory coccidioidomycosis treated with posaconazole | Q46503391 | ||
| In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi | Q46595795 | ||
| Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis | Q46620841 | ||
| A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. | Q46758165 | ||
| International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. | Q46784358 | ||
| Fluconazole prophylaxis for critically ill patients at high risk for Candida infection | Q46788982 | ||
| In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. | Q46801074 | ||
| Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities | Q46908044 | ||
| Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. | Q50700185 | ||
| Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. | Q51187145 | ||
| Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 | ||
| A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. | Q51187404 | ||
| The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. | Q51188122 | ||
| Risk factors for invasive fungal infections complicating orthotopic liver transplantation. | Q51195234 | ||
| Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. | Q52073846 | ||
| An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. | Q53349495 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group | Q54057550 | ||
| Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. | Q54171057 | ||
| Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. | Q54188180 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 614-645 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Current options in antifungal pharmacotherapy | |
| P478 | volume | 28 |
| Q37776005 | A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver functio |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q59135042 | An insight into new strategies to combat antifungal drug resistance |
| Q37204164 | Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. |
| Q38061087 | Antifungal susceptibility testing: a primer for clinicians |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q56993256 | Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications |
| Q93338789 | Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections |
| Q36846175 | Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus |
| Q38658275 | Development of antifungal therapies using nanomaterials |
| Q34169948 | Effectiveness of itraconazole on clinical symptoms and radiologic findings in patients with recurrent chronic rhinosinusitis and nasal polyposis |
| Q34419351 | Elucidating drug resistance in human fungal pathogens |
| Q38222570 | Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms |
| Q47882912 | Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies |
| Q46093154 | Immediate cross-hypersensitivity between micafungin and caspofungin: a case report. |
| Q38285488 | Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases |
| Q34328933 | Natural products: a continuing source of novel drug leads |
| Q37608276 | New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance |
| Q38918175 | PharmGKB summary: voriconazole pathway, pharmacokinetics |
| Q33568256 | Progress towards recombinant anti-infective antibodies |
| Q88376520 | Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole |
| Q41610197 | Reversible dilated cardiomyopathy associated with amphotericin B therapy. |
| Q35715408 | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
| Q38077591 | Safety of posaconazole |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
| Q38140015 | Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. |
| Q40442939 | Topical and systemic antifungals in dermatology practice. |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
Search more.